Keros Therapeutics, Inc. (KROS)
KROSNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$9.17
-0.1900 (-2.03%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $179.96m
- P/E
- –
- EPS, last 4 quarters
- $-2.82
- Dividend yield
- –
- Day range
- –
- 52-week range
- $9.26 to $22.55
- Average volume
- 172.4k
- Previous close
- $9.36
Analysts
4 coveringBuy2 buy, 2 hold, 0 sell
Targets a year out average $17.75, +93.6% from here
Earnings
next estimate $-1.72Next report
Dec 2025
-75.5%
Mar 2026
-31.5%
Jun 2026
-16.0%
Sep 2026
+172.9%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $14.26m | $385.0k | $367.0k | – |
| Gross profit | $14.26m | $385.0k | $367.0k | – |
| Operating income | -$15.38m | -$29.27m | -$25.88m | -$30.94m |
| Net income | -$7.28m | -$23.46m | -$23.71m | -$28.71m |
News
8 latest- Keros Therapeutics, Inc. Reports Third Quarter 2026 Financial ResultsFintel · 4 days ago
- Keros Therapeutics, Inc. (KROS) Q3 Earnings and Revenues Surpass EstimatesZacks · 4 days ago
- Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center StageMarketBeat · Oct 22, 2026
- Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?Zacks · Oct 7, 2026
- KROS Begins Dosing in Phase II Study With Rinvatercept in DMDZacks · Sep 29, 2026
- Keros Therapeutics Authorises $ 5 Mln Share Buyback Following Elritercept Milestone; Stock Up RTTNews · Sep 9, 2026
- Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?Zacks · Sep 2, 2026
- KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays WeakZacks · Aug 24, 2026
The company
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF- family of proteins. Keros is a leader in understanding the role of the TGF- family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros' lead product candidate, rinvatercept, is being developed for the treatment of DMD and for the treatment of amyotrophic lateral sclerosis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- kerostx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.